See the DrugPatentWatch profile for stiripentol

Stiripentol and fenfluramine are both medications used in the treatment of Dravet syndrome and Lennox-Gastaut syndrome, two severe forms of epilepsy. Stiripentol has shown effectiveness in reducing seizure frequency in patients with Dravet syndrome, particularly when used in combination with other antiepileptic drugs. On the other hand, fenfluramine has also demonstrated efficacy in reducing seizure frequency in patients with Dravet syndrome and Lennox-Gastaut syndrome. Both medications have shown promise in managing these difficult-to-treat epilepsies, with stiripentol often used in combination therapy and fenfluramine being a newer option with promising results. Patients should consult with their healthcare providers to determine the most appropriate treatment based on individual circumstances and medical history.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/STIRIPENTOL
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902175/
[3] https://www.neurologylive.com/view/the-impact-of-cannabidiol-fenfluramine-and-stiripentol-clobazam-for-treating-dravet-and-lennox-gastaut-syndromes